<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04517058</url>
  </required_header>
  <id_info>
    <org_study_id>EpComid</org_study_id>
    <nct_id>NCT04517058</nct_id>
  </id_info>
  <brief_title>A Prospective Cohort Study on the Comorbid Depression in Patients With Epilepsy</brief_title>
  <official_title>A Prospective, Multi-center, Cohort Study on Early Diagnosis and Treatment for Comorbid Depression in Patients With Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>the Tenth People's Hospital affiliated to Tongji University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>the Shanghai Seventh People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Epilepsy is a chronic brain disease with recurrent seizures and the comorbidity of&#xD;
      psychiatric diseases are very common. The prevalence of depression in patients with&#xD;
      refractory epilepsy is about 60%. However, the early diagnosis is usually difficult due to&#xD;
      the unclear mechanism and untypical clinical symptoms, and there are no extremely effective&#xD;
      treatments for depression in patients with epilepsy until now. In this prospective,&#xD;
      multi-center, cohort study, we aim to investigate and screen two different types of&#xD;
      depression (&quot;cognitive&quot; and &quot;somatic&quot;) in patients with epilepsy by using the combination of&#xD;
      regular moods evaluating scales and heart rate variability instrument. The intervening&#xD;
      methods of combining transcranial direct current stimulation (tDCS) and serotonin re-uptake&#xD;
      inhibitors (SSRIs) are used to treat the patients with comorbidity of epilepsy and&#xD;
      depression.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Epilepsy is a chronic brain disease with recurrent seizures and the comorbidity of&#xD;
      psychiatric diseases are very common. The prevalence of depression in patients with&#xD;
      refractory epilepsy is about 60%. However, the early diagnosis is usually difficult due to&#xD;
      the unclear mechanism and untypical clinical symptoms, and there are no extremely effective&#xD;
      treatments for depression in patients with epilepsy until now. In this prospective,&#xD;
      multi-center, cohort study, we aim to investigate and screen two different types of&#xD;
      depression (&quot;cognitive&quot; and &quot;somatic&quot;) in patients with epilepsy by using the combination of&#xD;
      regular moods evaluating scales and heart rate variability instrument. The intervening&#xD;
      methods of combining transcranial direct current stimulation (tDCS) and serotonin re-uptake&#xD;
      inhibitors (SSRIs) are used to treat the patients with comorbidity of epilepsy and&#xD;
      depression. And resting-state functional MRI will be conducted in patients with the&#xD;
      comorbidity of epilepsy and depression before and after the combing treatment of tDCS and&#xD;
      SSRIs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The reduction of HAMD score</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>&quot;Cognitive&quot; type depression group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HAMD-17 greater than 7 with negative HRV changes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>&quot;Somatic&quot; type depression group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HAMD-17 greater than 7 with positive HRV changes</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>transcranial direct current stimulation</intervention_name>
    <description>combining tDCS and SSRIs</description>
    <arm_group_label>&quot;Cognitive&quot; type depression group</arm_group_label>
    <arm_group_label>&quot;Somatic&quot; type depression group</arm_group_label>
    <other_name>SSRIs drugs</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  meeting the definition of epilepsy according to the new definition issued by ILAE in&#xD;
             2014&#xD;
&#xD;
          -  not using antidepressants&#xD;
&#xD;
          -  acquiring informed consents&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with severe psychiatric symptoms;&#xD;
&#xD;
          -  progressive brain diseases&#xD;
&#xD;
          -  malignant tumors&#xD;
&#xD;
          -  severe cognitive declines&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 15, 2020</study_first_submitted>
  <study_first_submitted_qc>August 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2020</study_first_posted>
  <last_update_submitted>August 17, 2020</last_update_submitted>
  <last_update_submitted_qc>August 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

